Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week, phase 2, multicenter, open-label, dose-finding trial and extension study

Key Findings

• Purpose
  To evaluate the efficacy, safety, and optimal dosing of osivelotor, a sickle hemoglobin (HbS) polymerization inhibitor, in adults with sickle cell disease (SCD), and to assess the durability of response during an open-label extension (OLE) study.
• Population (Model)
  Phase 2 randomized (1:1), multicenter, open-label, dose-finding trial involving 54 adults (18–65 years) with HbSS or HbSβ⁰-thalassemia and baseline hemoglobin 5.5–10.5 g/dL. Participants received osivelotor 100 mg or 150 mg once daily following a four-day loading regimen. Forty-six participants continued into the OLE study.
• Headline Result
  Osivelotor produced rapid and sustained hemoglobin improvements. Mean hemoglobin increased by +2.6 g/dL with the 100-mg dose and +3.4 g/dL with the 150-mg dose by Week 12. More than 95% of participants achieved a hemoglobin increase greater than 1 g/dL, while approximately 70–78% achieved increases greater than 2 g/dL. Improvements in hemoglobin were accompanied by favorable changes in markers of hemolysis and were maintained through the OLE. Exploratory analyses also suggested lower annualized vaso-occlusive crisis (VOC) rates during treatment compared with the pre-screening period.
• Why It Matters
  

  Chronic anemia and hemolysis remain central drivers of morbidity in SCD. This phase 2 study suggests that inhibition of HbS polymerization with osivelotor can produce rapid, clinically meaningful, and sustained improvements in hemoglobin while improving laboratory markers of hemolysis. The exploratory reduction in VOC rates is encouraging but should be interpreted cautiously because the study was not designed or powered to formally evaluate clinical event reduction.

• Evidence Gaps & Limitations
  This was a relatively small, open-label phase 2 study without a placebo control, limiting conclusions regarding comparative efficacy and clinical outcomes. VOC analyses were exploratory, and the study was not powered to demonstrate reductions in vaso-occlusive events. Although the safety profile was generally favorable, larger randomized phase 3 studies are needed to confirm long-term efficacy, safety, and clinical benefit across broader SCD populations.

Source: Journal of Sickle Cell Disease- “Efficacy and safety of osivelotor in participants with sickle cell disease in a 12-week, phase 2, multicenter, open-label, dose-finding trial and extension study”

Regulatory & Guideline Watch

Osivelotor remains an investigational therapy and has not been incorporated into current SCD treatment guidelines. This phase 2 study provides evidence supporting continued clinical development, particularly for improving anemia and hemolysis. Confirmation of long-term clinical benefits, including effects on VOCs and other disease complications, will require larger randomized trials before guideline recommendations can be considered.